Abstract
Objective: To assess the efficacy of statin therapy on early stage chronic kidney disease through an overview of systematic reviews.
Methods: We searched for systematic reviews of randomized clinical trials (RCT) on MEDLINE, Embase, Cochrane Library, CRD, and Scopus. Independent reviewers selected the studies and extracted the relevant data. We critically appraised the included systematic reviews with the AMSTAR tool and presented the available data in the studies.
Results: From 731 retrieved records, we included three systematic reviews. Statins reduced the risk of mortality for all causes and for cardiovascular causes in patients with early stage chronic kidney disease as compared to the control (highquality evidence). Statins also reduced the incidence of any myocardial infarction, non-fatal myocardial infarction, and stroke (moderate- to high-quality evidence). No differences were observed between statins and control upon the incidence of end-stage renal disease or on the outcomes assessed in patients with coronary artery disease and diabetes.
Conclusion: Statins reduce the incidence of death and other relevant outcomes in patients with early stage chronic kidney disease and should be considered for such individuals who also present hyperlipidemia.
Keywords: Chronic renal insufficiency, hydroxymethylglutaryl-CoA reductase inhibitors, kidney diseases, review
Cardiovascular & Hematological Disorders-Drug Targets
Title:Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews
Volume: 14 Issue: 3
Author(s): Tais F. Galvao, Maria Elizete A. Araujo, Anderson P. Penha and Marcus T. Silva
Affiliation:
Keywords: Chronic renal insufficiency, hydroxymethylglutaryl-CoA reductase inhibitors, kidney diseases, review
Abstract: Objective: To assess the efficacy of statin therapy on early stage chronic kidney disease through an overview of systematic reviews.
Methods: We searched for systematic reviews of randomized clinical trials (RCT) on MEDLINE, Embase, Cochrane Library, CRD, and Scopus. Independent reviewers selected the studies and extracted the relevant data. We critically appraised the included systematic reviews with the AMSTAR tool and presented the available data in the studies.
Results: From 731 retrieved records, we included three systematic reviews. Statins reduced the risk of mortality for all causes and for cardiovascular causes in patients with early stage chronic kidney disease as compared to the control (highquality evidence). Statins also reduced the incidence of any myocardial infarction, non-fatal myocardial infarction, and stroke (moderate- to high-quality evidence). No differences were observed between statins and control upon the incidence of end-stage renal disease or on the outcomes assessed in patients with coronary artery disease and diabetes.
Conclusion: Statins reduce the incidence of death and other relevant outcomes in patients with early stage chronic kidney disease and should be considered for such individuals who also present hyperlipidemia.
Export Options
About this article
Cite this article as:
Galvao F. Tais, Araujo Elizete A. Maria, Penha P. Anderson and Silva T. Marcus, Statins for Early Stage Chronic Kidney Disease: An Overview of Reviews, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140401114301
DOI https://dx.doi.org/10.2174/1871529X14666140401114301 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Formulation and Pharmacodynamic Evaluation of Glibenclamide Incorporated Niosomal Gel
Current Drug Discovery Technologies Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Type 2 Diabetes and Risk for Functional Decline and Disability in Older Persons
Current Diabetes Reviews Anti-diabetic Phenolic Compounds of Black Carrot (Daucus carota Subspecies sativus var. atrorubens Alef.) Inhibit Enzymes of Glucose Metabolism: An in silico and in vitro Validation
Medicinal Chemistry Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews Regulation of Intestinal Chylomicron Production by Glucagon-Like Peptides
Cardiovascular & Hematological Disorders-Drug Targets Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Etiology of the Metabolic Syndrome
Current Cardiology Reviews New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis
Current Diabetes Reviews A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State
Vascular Disease Prevention (Discontinued) <i>Dillenia Indica</i> Fruit Extract Suppressed Diet-induced Obesity in Rats by Down-regulating the mRNA Level of Proadipogenic Transcription Factors and Lipid Metabolizing Enzymes
Current Nutrition & Food Science